0001209191-16-148721.txt : 20161107 0001209191-16-148721.hdr.sgml : 20161107 20161107184104 ACCESSION NUMBER: 0001209191-16-148721 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161103 FILED AS OF DATE: 20161107 DATE AS OF CHANGE: 20161107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 MILK STREET STREET 2: 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 50 MILK STREET STREET 2: 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zorn Peter A CENTRAL INDEX KEY: 0001357865 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 161979539 MAIL ADDRESS: STREET 1: C/O TARGACEPT, INC. STREET 2: 2200 EAST FIRST STREET, SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-11-03 0 0001322505 ALBIREO PHARMA, INC. ALBO 0001357865 Zorn Peter A C/O ALBIREO PHARMA INC. 50 MILK STREET, 16TH FLOOR BOSTON MA 02109 0 1 0 0 Senior VP, Corp Dev, GC & Sec Common Stock 2016-11-03 4 A 0 934 0.00 A 934 D Stock Option (right to buy) 1.00 2016-11-03 4 A 0 52441 0.00 A 2026-04-14 Common Stock 52441 52441 D Represents shares of common stock of Albireo Pharma, Inc. (the "Issuer"), formerly known as Biodel Inc., issued in the share exchange transaction that was completed on November 3, 2016 pursuant to an Amended and Restated Share Exchange Agreement, dated as of July 13, 2016, by and among Biodel Inc., Albireo Limited ("Albireo") and the holders of Albireo shares and notes convertible into Albireo shares. This option was issued in replacement of an option to purchase shares of Albireo Limited. This option is vested and exercisable as to 33.33% of the underlying shares on the grant date, with the remainder vesting and becoming exercisable in 32 equal installments on the first day of each calendar month beginning with December 1, 2016 and ending July 1, 2019. /s/ Peter A. Zorn 2016-11-07